University of Utah Health: College of Pharmacy Program Awarded $34M Contract Renewal to Test and Identify Investigational Therapeutics That Prevent and Treat Drug-Resistant Epilepsy
May 17, 2022
May 17, 2022
SALT LAKE CITY, Utah, May 17 (TNSfund) -- The University of Utah Health issued the following news release:
The University of Utah College of Pharmacy's Anticonvulsant Drug Development (ADD) Program has been awarded a five-year $34 million contract renewal with the NIH's National Institute of Neurological Disorders and Stroke (NINDS) to test and identify novel investigational therapeutics for preventing the development of epilepsy and treating refractory, or drug-resistant, . . .
The University of Utah College of Pharmacy's Anticonvulsant Drug Development (ADD) Program has been awarded a five-year $34 million contract renewal with the NIH's National Institute of Neurological Disorders and Stroke (NINDS) to test and identify novel investigational therapeutics for preventing the development of epilepsy and treating refractory, or drug-resistant, . . .